Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) ± Rituximab + Recombinant Erwinia Asparaginase (JZP458; Rylaze®) for the Treatment of Newly-Diagnosed Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Lymphoma/Leukemia

This phase II trial tests how well etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH) with or without rituximab plus recombinant Erwinia asparaginase (JZP458) works in treating patients with newly diagnosed Philadelphia chromosome (Ph) negative B-acute lymphoblastic leukemia (ALL) or T-ALL. Chemotherapy drugs, such as etoposide, vincristine, cyclophosphamide and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as prednisone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. JZP458 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving DA-EPOCH with or without rituximab plus JZP458 may kill more cancer cells in patients with newly diagnosed Ph negative B-ALL or T-ALL.

开始日期2025-06-01

申办/合作机构

University of Washington

[+1]

NCT06692452 / Not yet recruiting临床2期IIT

A Phase II Study of Tazemetostat in Combination with CHOP for Previously Untreated T Cell Lymphoma

This research is being done to evaluate tazemetostat in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy as a possible treatment for peripheral T-Cell Lymphoma (PTCL).
The name of the study drugs involved in this study are:
* Tazemetostat (a type of inhibitor for Enhancer of Zeste Homolog 2 (EZH2))
* Standard of care CHOP therapy:
* Cyclophosphamide (a type of alkylating agent)
* Doxorubicin (a type of anthracycline antibiotic)
* Vincristine (a type of vinca alkaloid)
* Prednisone (a type of corticosteroid)
* Standard of care BEAM conditioning regimen for autologous stem cell transplant:
* Carmustine (a type of alkylating agent)
* Etoposide (a type of Topoisomerase II inhibitor)
* Cytarabine (a type of antineoplastic)
* Melphalan (a type of alkylating agent)

开始日期2025-04-01

申办/合作机构

Dana-Farber Cancer Institute, Inc.

[+1]

NCT06401330 / Not yet recruiting临床3期IIT

Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)

This phase III trial studies using risk factors in determining treatment for children with favorable tissue (histology) Wilms tumors (FHWT). Wilms Tumor is the most common type of kidney cancer in children, and FHWT is the most common subtype. Previous large clinical trials have established treatment plans that are likely to cure most children with FHWT, however some children still have their cancer come back (called relapse) and not all survive. Previous research has identified features of FHWT that are associated with higher or lower risks of relapse. The term "risk" refers to the chance of the cancer coming back after treatment. Using results of tumor histology tests, biology tests, and response to therapy may be able to improve treatment for children with FHWT.

开始日期2025-03-31

申办/合作机构

The Children's Oncology Group Foundation, Inc.

100 项与依托泊苷相关的临床结果

登录后查看更多信息

100 项与依托泊苷相关的转化医学

登录后查看更多信息

100 项与依托泊苷相关的专利（医药）

登录后查看更多信息

23,543

项与依托泊苷相关的文献（医药）

2025-02-01·Current Computer-Aided Drug Design

Computer-aided Drug Discovery Approaches in the Identification of Anticancer Drugs from Natural Products: A Review

Review

作者: Priya, Muthiah Gnana Ruba ; Manisha, Jessica ; Lazar, Lal Prasanth Mercy ; Rathore, Seema Singh ; Solomon, Viswas Raja

Natural plant sources are essential in the development of several anticancer drugs, such as vincristine, vinblastine, vinorelbine, docetaxel, paclitaxel, camptothecin, etoposide, and teniposide. However, various chemotherapies fail due to adverse reactions, drug resistance, and target specificity. Researchers are now focusing on developing drugs that use natural compounds to overcome these issues. These drugs can affect multiple targets, have reduced adverse effects, and are effective against several cancer types. Developing a new drug is a highly complex, expensive, and time-consuming process. Traditional drug discovery methods take up to 15 years for a new medicine to enter the market and cost more than one billion USD. However, recent Computer Aided Drug Discovery (CADD) advancements have changed this situation. This paper aims to comprehensively describe the different CADD approaches in identifying anticancer drugs from natural products. Data from various sources, including Science Direct, Elsevier, NCBI, and Web of Science, are used in this review. In-silico techniques and optimization algorithms can provide versatile solutions in drug discovery ventures. The structure-based drug design technique is widely used to understand chemical constituents' molecular-level interactions and identify hit leads. This review will discuss the concept of CADD, in-silico tools, virtual screening in drug discovery, and the concept of natural products as anticancer therapies. Representative examples of molecules identified will also be provided.

2025-02-01·BLOOD CELLS MOLECULES AND DISEASES

Hemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitor use: A review of the current knowledge and future directions

Review

作者: Rangachari, Deepa ; Berwick, Shana ; Schoepflin, Zachary ; De Brabandt, Charlotte ; Walmsley, Charlotte S ; Patell, Rushad ; Walmsley, Charlotte S.

Hemophagocytic lymphohistiocytosis (HLH) is a severe and often lethal inflammatory syndrome characterized by excessive immune activation leading to fever, cytopenias, and multiorgan involvement. Immune checkpoint inhibitors (ICIs) are central to many contemporary cancer regimens, but their use is associated with immune-related adverse events. Here, we report a case of ICI-induced HLH successfully treated with single agent dexamethasone and provide a scoping review of the literature for cases of ICI-induced HLH with a focus on treatment strategies and outcomes. Using the Medline database, we searched for cases of ICI-associated HLH, with a total of 51 cases reported between 2017 and 2023. Our results underscore the severe nature of this disease, with a 13.7 % mortality rate across 51 case reports. Treatment strategies for ICI-induced HLH were variable: steroids alone (56.9 %), steroids with etoposide (17.6 %), steroids with tociluzumab (11.8 %), among other combinations. Our literature review indicates that steroids alone may be sufficient treatment in some cases of ICI-HLH, with comparable mortality with steroids alone (n = 29) (13.8 %) to that of cases treated with both steroids and immunomodulators (n = 15, 13.3 %). Moreover, all patients treated with steroids and tocilizumab survived (n = 6), suggesting that tocilizumab may be a reasonable next line of therapy when steroid monotherapy proves inadequate. We propose an outline for investigation and treatment of this rare complication of ICI use. Finally, we discuss possible future approaches to develop evidence-based strategies for the diagnosis and management of ICI-induced HLH including the importance of integrating the role of patient community involvement.

2025-02-01·PROSTATE

Protein kinase D1 mitigation against etoposide induced DNA damage in prostate cancer is associated with increased α‐Catenin

Article

作者: Krishnan, Sunil ; Osumi, Teruko ; Chardon‐Robles, Jonathan ; Singh, Pankaj kumar ; Shukla, Sanjeev ; McKenna, Robert ; Al‐Toubat, Mohammed ; Mietzsch, Mario ; Serrano, Samuel ; Balaji, K. C.

Abstract:

Background:

The E‐cadherin, α‐ and β‐Catenin interaction at the cell adherens junction plays a key role in cell adhesion; alteration in the expression and function of these genes are associated with disease progression in several solid tumors including prostate cancer. The membranous β‐Catenin is dynamically linked to the cellular cytoskeleton through interaction with α‐Catenin at amino acid positions threonine 120 (T120) to 151 of β‐Catenin. Nuclear presence of α‐Catenin modulates the sensitivity of cells to DNA damage. The objective of this study is to determine the role of α‐Catenin and protein kinase D1 (PrKD1) in DNA damage response.

Methods:

Prostate cancer cells; LNCaP, LNCaP (Sh‐PrKD1; silenced PrKD1), C4‐2 and C4‐2 PrKD1 were used for various sets of experiments to determine the role of DNA damage in PrKD1 overexpression and silencing cells. These cells were treated with compound‐10 (100 nM) and Etoposide (30 µM), total cell lysates, cytosolic and nuclear fractions were prepared to observe various protein expressions. We performed single cell gel electrophoresis (COMET assay) to determine the etoposide induce DNA damage in C4‐2 and C4‐2 PrKD1 cells. The animal experiments were carried out to determine the tolerability of compound‐10 by mice and generate preliminary data on efficacy of compound‐10 in modulating the α‐Catenin and PrKD1 expressions in inhibiting tumor progression.

Results:

PrKD1, a novel serine threonine kinase, phosphorylates β‐Catenin T120. In silico analysis, confirmed that T120 phosphorylation alters β‐ to α‐Catenin binding. Forced expression of PrKD1 in prostate cancer cells increased β‐ and α‐Catenin protein levels associated with reduced etoposide induced DNA damage. Downregulation of α‐Catenin abrogates the PrKD1 mitigation of DNA damage. The in vitro results were corroborated in vivo using mouse prostate cancer patient derived xenograft model by inhibition of PrKD1 kinase activity with compound‐10, a selective PrKD inhibitor, demonstrating decreased total β‐ and α‐Catenin protein levels, and β‐Catenin T120 phosphorylation.

Conclusions:

Alteration in DNA damage response pathways play major role in prostate cancer progression. The study identifies a novel mechanism of α‐Catenin dependent DNA damage mitigation role for PrKD1 in prostate cancer.

596

项与依托泊苷相关的新闻（医药）

2024-12-23

·正大天晴药业集团

2024新药成绩单，正大天晴领跑肿瘤1类创新药赛道

2024年进入尾声，今年中国再次迎来上百款新药获批上市。根据国家药监局（NMPA）官网批件信息及公开资料统计，2024年以来（截至12月16日），全国共有超90款新药获NMPA批准上市，1类创新药近40款，其中有18款是抗肿瘤用药，占首次获批上市1类创新药的47%。正大天晴聚焦肿瘤治疗领域，今年共推出4款1类创新药，国内领跑。（此处“新药”的统计范围包括：化学药品1类和5.1类、治疗用生物制品1类和3.1类，以及少数几款以2.2类和2.4类申报的新药，不含疫苗类产品）富马酸安奈克替尼胶囊富马酸安奈克替尼胶囊（商品名：安柏尼）是首个获批用于ROS1阳性的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者的国产靶向药，对ALK、ROS1和MET基因突变均有较强的抑制作用。2024年世界肺癌大会（WCLC）上公布的一项Ⅱ期临床结果显示，总体人群客观缓解率（ORR）提升至81.08%，中位无进展生存期（PFS）延长至17.25个月，24个月总生存期（OS）达82.18%[1]。贝莫苏拜单抗注射液贝莫苏拜单抗注射液（商品名：安得卫）获批的首个适应症是联合安罗替尼胶囊和依托泊苷及卡铂一线治疗广泛期小细胞肺癌（ES-SCLC）。这是一款全新序列的创新抗PD-L1人源化单克隆抗体，发表于国际权威医学期刊《Nature Medicine》（IF=58.7）的ETER701临床结果显示，接受贝莫苏拜单抗四药联合疗法的患者中位OS达19.3个月，较单纯化疗组延长了7.4个月[2]。 11月，贝莫苏拜单抗联合安罗替胶囊获批新适应症。用于治疗既往接受过一、二线化疗方案治疗失败或不能耐受的非微卫星高度不稳定（非MSI-H）或非DNA错配修复缺陷（非dMMR）的复发性或转移性子宫内膜癌。12月15日，第四届中国生化制药行业高质量发展大会上，贝莫苏拜单抗获评2024年度“生化、生物药品优秀品牌”。枸橼酸依奉阿克胶囊新一代ALK抑制剂枸橼酸依奉阿克胶囊（商品名：安洛晴）的首个适应症是用于治疗未经过ALK抑制剂治疗的ALK阳性的局部晚期或转移性非小细胞肺癌（NSCLC）患者。发表于《Signal Transduction and Targeted Therapy》（IF：40.8）一项对比一代ALK抑制剂的Ⅲ期临床结果显示，受试者中位PFS分别为24.87个月、11.6个月。针对存在可脑转移病灶的患者，ORR分别为78.95%、23.81%，DOR分别为25.82个月、7.39个月，均高于对照组[3]。格索雷塞片格索雷塞片（商品名：安方宁）的首个适应症是用于治疗至少接受过一种系统性治疗的KRAS G12C突变型的晚期非小细胞肺癌（NSCLC）成人患者。格索雷塞是正大天晴与益方生物合作开发的一款KRAS G12C选择性抑制剂。2024年世界肺癌大会（WCLC）上公布的一项Ⅱ期临床结果显示，受试者ORR达52.0%，DCR达88.6%，中位PFS为9.1个月，中位OS为14.1个月[4]。今年，正大天晴还有两款自主研发的肿瘤1类新药——罗伐昔替尼片、库莫西利胶囊申报上市，并获得国家药品监督管理局药品审评中心（CDE）受理。其中，库莫西利胶囊是一款CDK2/4/6抑制剂，用于治疗乳腺癌；罗伐昔替尼片是一款JAK/ROCK抑制剂，用于治疗骨髓纤维化。随着更多创新产品的密集上市，饱受癌症困扰的患者将有望获得更为精准、高效的治疗方案。参考文献： [1] Ziming Li et al.Unecritinib in Patients with ROS1 Positive Advanced Non-Small Cell Lung Cancer: Updated Results from a Phase II Trial. WCLC 2024; MA06.04_0813. [2] Cheng, Y., Chen, J., Zhang, W. et al. Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial. Nat Med (2024). [3] Yang Y, Min J, Yang N, et al. Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial.Signal Transduction and Targeted Therapy. 2023;8(1):301. [4] Z. Li, et al. Garsorasib in KRAS G12C-mutated Non-small-cell Lung Cancer: Updated Results from a Phase 2 Study. 2024-LBA-1246-WCLC. 声明： 1. 本新闻稿旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参阅，非广告用途。 2. 本公司不对任何药品和/或适应症作推荐。 3. 本新闻稿中涉及的信息仅供参考，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。内容来源：医药观澜 ● 中国生物制药与国药控股签署战略合作协议 ● 正大天晴贝莫苏拜单抗荣获“生化、生物药品优秀品牌” ● 2024 SABCS|正大天晴公布安罗替尼治疗乳腺癌最新数据 ● BEAMION LUNG-1研究的最新数据：zongertinib展现振奋人心的疗效，为HER2突变非小细胞肺癌经治患者带来希望

临床3期临床结果上市批准

2024-12-20

·恒瑞医药

恒瑞医药创新药SHR-1501联合阿得贝利单抗用于膀胱癌获批临床

近日，恒瑞医药子公司上海恒瑞医药有限公司和上海盛迪医药有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，批准公司开展注射用SHR-1501（膀胱灌注）联合阿得贝利单抗注射液（静脉注射）用于非肌层浸润性膀胱癌的临床试验。尿路上皮癌（UC）主要包括肾盂、输尿管、膀胱的移行上皮恶性肿瘤，其中膀胱癌约占90%。2020年，全球范围内膀胱癌新发病例约57万例，死亡约21万例，在所有恶性肿瘤中分别排第12位和第14位1。根据国家癌症中心发布的国内癌症统计报告，2022年国内新发膀胱癌病例约9.3万例，死亡约4.1万例，在所有恶性肿瘤中排第11位2。非肌层浸润性膀胱癌（NMIBC）是指局限于膀胱黏膜层及固有层，且肌层未见浸润的膀胱恶性肿瘤，约75%膀胱癌的患者初诊时为NMIBC3。经尿道膀胱肿瘤切除术（TURBT）是NMIBC的标准治疗方式，也是重要诊断方法。NMIBC在TURBT术后复发率高4 ，因此推荐所有NMIBC患者进行术后辅助性膀胱灌注治疗，包括膀胱灌注化疗和膀胱灌注免疫治疗。对于高危NMIBC患者，推荐术后膀胱灌注卡介苗（BCG），预防复发及进展。依据2024 NCCN指南及2024 CSCO指南推荐，BCG经治失败的高危NMIBC标准治疗手段为根治性膀胱全切，膀胱全切后对患者生活影响很大，且带来沉重的经济负担。BCG经治失败的高危NMIBC目前缺乏有效的治疗手段保留膀胱，临床急需研发新的治疗药物，避免或延缓膀胱全切的时间。 SHR-1501是恒瑞医药自主研发并具有知识产权的白细胞介素-15（IL-15）融合蛋白，可以刺激体内T细胞、B细胞和NK细胞增殖，发挥调动机体免疫系统清除体内异物（如肿瘤）的作用。与IL-2相比，IL-15不会刺激调节性T细胞增殖和诱导T细胞凋亡。目前国内未有相同靶点产品获批上市。阿得贝利单抗注射液是恒瑞医药自主研发的人源化抗PD-L1单克隆抗体，能通过特异性结合PD-L1分子从而阻断导致肿瘤免疫耐受的PD-1/PD-L1通路，重新激活免疫系统的抗肿瘤活性，从而达到治疗肿瘤的目的。公司阿得贝利单抗注射液（商品名：艾瑞利®）已于2023年3月获批上市，获批适应症为与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。该产品已被北京、上海、成都等多地纳入“惠民保”特药报销目录。公司现有多项阿得贝利单抗注射液临床研究正在进行，以评估其在非小细胞肺癌、小细胞肺癌、食管癌、肝癌等多种实体瘤中的抗肿瘤作用。参考文献： 1.Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49. 2.Han B, Zheng R, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024 Feb 2;4(1):47-53. 3.Ro JY, Staerkel GA, et al. Cytologic and histologic features of superficial bladder cancer. Urol Clin North Am. 1992 Aug;19(3):435-53. PMID: 1636229. 4.Chang SS, Boorjian SA, Chou R, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol 2016;196:1021-9. 声明： 1.本新闻旨在分享研发前沿资讯，仅供医疗卫生专业人士参阅，非广告用途。 2.恒瑞医药不推荐任何未被批准的药品、适应症的使用。撰稿：王文亮高等会排版：程梦真责编：王玲往期精选 | 研发创新 | 慢病创新里程碑！恒瑞首个自免创新药夫那奇珠单抗获批上市恒瑞医药新突破！中国首个自研阿片类镇痛创新药富马酸泰吉利定获批上市 | 国际化 | 海外BD再传捷报！恒瑞医药GLP-1类创新药组合实现海外许可恒瑞医药与默克达成合作，携手推进癌症创新疗法 | 重磅奖项 | 喜报！恒瑞医药荣获2023年度国家科技进步奖恒瑞医药连续六年入选全球制药企业50强榜单！ | 社会公益 | “健康中国行·重走长征路”项目启动仪式圆满举行！恒瑞提供公益支持，助力健康中国恒瑞医药集团向中国扶贫基金会捐赠3000万设立“健康帮扶基金”

CSCO会议上市批准免疫疗法

2024-12-19

·摩熵医药

正大天晴贝莫苏拜单抗新适应症 III 期临床成功！

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 12月19日，正大天晴宣布，其1类新药贝莫苏拜单抗联合或不联合盐酸安罗替尼胶囊用于巩固治疗同步/序贯放化疗后未进展的、局部晚期/不可切除（III 期）的非小细胞肺癌（NSCLC）患者的 III 期临床研究（TQB2450-III-05）取得显著进展，主要研究终点无进展生存期（PFS）达到方案预设的优效界值。截图来源：摩熵医药（原药融云）中国临床试验数据库 TQB2450-III-05研究（NCT04325763），作为一项精心设计的随机、双盲双模拟、安慰剂平行对照、多中心III期临床研究，其核心目的在于深入探索贝莫苏拜单抗——正大天晴自主研发的PD-L1单抗，在联合或不联合盐酸安罗替尼胶囊作为巩固治疗手段时，对于同步/序贯放化疗后病情稳定的局部晚期/不可切除（III期）非小细胞肺癌（NSCLC）患者的疗效与安全性。期中分析振奋人心地揭示，相较于对照组，试验组在降低患者疾病进展或死亡风险方面展现出了显著优势，患者的无进展生存期（PFS）得到了明显延长。同时，其安全性数据与已知风险保持一致，未发现任何新的安全性隐患。截图来源：摩熵医药（原药融云）中国临床试验数据库这一研究的突破性成果，无疑为那些经历同步/序贯放化疗后病情稳定的局部晚期/不可切除（III期）NSCLC患者点亮了新的治疗曙光。正大天晴已顺利获得CDE对该适应症上市申请的书面认可，并正紧锣密鼓地准备近期递交上市申请，有望为更多患者带来福音。值得一提的是，贝莫苏拜单抗在今年已相继斩获两项适应症批准：一是联合盐酸安罗替尼胶囊、卡铂和依托泊苷，作为广泛期小细胞肺癌（ES-SCLC）患者的一线治疗选择；二是携手盐酸安罗替尼胶囊，针对既往系统性抗肿瘤治疗失败且不适宜进行根治性手术或放疗的非微卫星高度不稳定（非MSI-H）或非错配修复基因缺陷（非dMMR）的复发性或转移性子宫内膜癌患者提供治疗新方案。展望未来，贝莫苏拜单抗的研发市场远不止于此。据摩熵医药数据库最新数据显示，该药已广泛布局多个适应症领域，其中肾细胞癌的上市申请已进入关键阶段，另有包括NSCLC在内的五个癌种正处于III期临床研究的积极阶段，涵盖卵巢上皮癌、乳腺癌、肝细胞癌及胆道癌，展现出广阔的应用前景与无限潜力。 END 本文为原创文章，转载请留言获取授权近期热门资源获取后台回复关键词“深度报告”，获取价值18600元，报告大礼包后台回复关键词“2023首仿”，获取2023年首仿药物获批名单后台回复“GLP-1深度报告”，获取完整《GLP-1产业现状与未来发展》PDF版。后台回复“中国 I 类新药”，获取完整《中国 I 类新药靶点》PDF版。后台回复“NAFLD/NASH”，获取完整《NAFLD/NASH报告》PDF版。后台回复“AI+制药”，获取完整《中国AI制药企业白皮书》PDF版。后台回复“XXG”，获取完整《中国心血管系统药物分析报告》PDF版。后台回复“FZZJ”，获取完整《基于剂型改良的复杂注射剂分析》PDF版。后台回复“药品进出口”，获取完整《中国药品进出口白皮书》深度报告-PDF版。联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作 👆👆👆点击上方图片，即可开启摩熵化学数据查询点击阅读原文，申请摩熵医药企业版免费试用！

临床3期临床成功临床结果医药出海引进/卖出

100 项与依托泊苷相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00125	依托泊苷	L01CB01	DB00773

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
膀胱癌	日本	Clinigen Ltd.	1987-04-30
白血病	日本	Clinigen Ltd.	1987-04-30
淋巴瘤	日本	Nippon Kayaku Co., Ltd.	1987-03-31
卵巢癌	日本	Nippon Kayaku Co., Ltd.	1987-03-31
宫颈癌	日本	Nippon Kayaku Co., Ltd.	1987-03-31
小细胞肺癌	美国	Corden Pharma Latina SpA	1983-11-10
睾丸肿瘤	美国	Corden Pharma Latina SpA	1983-11-10

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
铂耐药性卵巢癌	临床3期	中国	江苏恒瑞医药股份有限公司	2019-08-16
原发部位不明恶性肿瘤	临床3期	美国	Pharmacia & Upjohn, Inc.	2003-09-01
原发部位不明恶性肿瘤	临床3期	美国	AstraZeneca PLC	2003-09-01
原发部位不明恶性肿瘤	临床3期	美国	Eli Lilly & Co.	2003-09-01
广泛期小细胞肺癌	临床3期	美国	GSK Plc	2001-04-01
广泛期小细胞肺癌	临床3期	中国	GSK Plc	2001-04-01
广泛期小细胞肺癌	临床3期	奥地利	GSK Plc	2001-04-01
广泛期小细胞肺癌	临床3期	比利时	GSK Plc	2001-04-01
广泛期小细胞肺癌	临床3期	巴西	GSK Plc	2001-04-01
广泛期小细胞肺癌	临床3期	保加利亚	GSK Plc	2001-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02705508 (Pubmed \| Hematology) 人工标引	临床2期	结外NK-T细胞淋巴瘤一线	34	PEG (pegaspargase, etoposide, gemcitabine)	積壓網選製襯憲範願鏇(製獵鏇憲壓顧網廠糧築) = 積繭積範膚廠艱鏇築艱顧積廠鹽廠鹹鹹範築獵 (憲遞膚蓋膚夢積構構餘 ) 更多	积极	2024-12-31
NCT00801216 (SCNSL1, CTgov)	临床2期	中枢神经系统疾病 \| B细胞淋巴瘤	40	etoposide+cyclophosphamide+carmustine+Rituximab+methotrexate+Thiotepa+cytarabine	鹹餘淵獵鏇醖鹹製繭膚(夢製齋齋襯網窪窪餘膚) = 廠鑰窪繭鹽積遞鹽範廠蓋淵繭網鏇鏇糧遞餘艱 (糧繭觸築憲顧鑰鏇築構, 齋範築壓獵製蓋夢簾遞 ~ 鹽衊顧鬱餘壓範製窪壓) 更多	-	2024-12-10
ASH2024	N/A	多发性骨髓瘤	-	Etoposide + G-CSF	願廠觸廠簾憲顧夢選製(鏇鹽襯獵夢膚築襯顧襯) = The primary adverse events were grade III-IV bone marrow suppression (100%) and febrile neutropenia (22.7%), with no documented bloodstream infections or hepatorenal toxicity 積構觸夢膚網蓋齋襯鏇 (鏇齋鏇觸艱顧製廠觸範 )	-	2024-12-07
NCT04951115 (CTgov)	临床2期	小细胞肺癌	6	Stereotactic Body Radiotherapy+Etoposide+Carboplatin+Cisplatin+Durvalumab	築餘膚範觸遞醖製廠簾(顧顧鏇選齋餘艱蓋願鹹) = 繭鏇鬱築製淵繭繭淵衊醖窪膚網繭鏇醖築膚製 (蓋鑰衊襯顧齋衊積夢願, 願築膚憲鬱壓選網鏇繭 ~ 簾築範鏇構築觸糧網淵) 更多	-	2024-11-26
NCT03923179 (ESMO2024) 人工标引	临床2期	HER2阳性转移性乳腺癌 HER2 Positive	22	Pyrotinib 400mg per dayetoposide	鑰願齋襯鹽繭選簾獵膚(衊築醖醖製鏇繭選衊鑰) = 構範夢積憲衊網願構鹽憲構餘醖衊願築糧醖衊 (膚製淵觸範顧膚膚網齋, 7.6 ~ 10.4) 更多	积极	2024-09-16
ESMO2024 人工标引	N/A	弥漫性大B细胞淋巴瘤 G6PD deficiency	82	RituximabCyclophosphamideDoxorubicin HydrochlorideVincristine SulfatePrednisone	範艱蓋選選蓋襯願製糧(餘鹽淵積觸淵窪築蓋網) = 膚鏇窪襯遞蓋鬱鑰糧廠糧選願顧網遞糧製製壓 (製襯憲艱淵鬱糧艱願衊 ) 更多	不佳	2024-09-15
				RituximabCyclophosphamideEtoposideVincristine SulfatePrednisone	範艱蓋選選蓋襯願製糧(餘鹽淵積觸淵窪築蓋網) = 觸艱憲選淵餘繭壓夢觸糧選願顧網遞糧製製壓 (製襯憲艱淵鬱糧艱願衊 ) 更多
JPRN-jRCTs031180216 (JCOG1205/1206, ESMO2024) 人工标引	临床3期	肺神经内分泌肿瘤	221	Etoposide/cisplatin (EP)	選網構鹽遞糧糧廠衊鏇(簾蓋夢餘繭範窪廠鹽襯) = 範網簾淵餘淵製夢顧觸網鹽簾積積選繭構顧糧 (鏇餘餘壓餘糧餘鏇簾壓 ) 更多	不佳	2024-09-14
				Irinotecan/cisplatin (IP)	選網構鹽遞糧糧廠衊鏇(簾蓋夢餘繭範窪廠鹽襯) = 獵餘獵遞獵構憲餘衊願網鹽簾積積選繭構顧糧 (鏇餘餘壓餘糧餘鏇簾壓 ) 更多
ESMO_ASIA2024	N/A	广泛期小细胞肺癌一线	274	Cisplatin (CDDP)+Etoposide (ETP)+Durvalumab (DUR)	醖糧範醖憲鬱繭齋顧範(選衊艱憲遞窪糧網網壓) = 8% vs. 4% 艱膚鹹顧窪觸窪積鹹衊 (糧築獵膚範糧築餘築簾 ) 更多	积极	2024-09-14
				Carboplatin (CBDCA)+ETP+Atezolizumab (ATZ)
WCLC2024 人工标引	N/A	非小细胞肺癌 III期	202	Cisplatin-etoposide	築廠齋醖餘壓範製淵製(製廠鏇齋築壓鏇網網膚) = CP was better tolerated with a lower incidence of grade 3-4 adverse events, including hematologic and gastrointestinal toxicities, compared to PE regimens. 47 (23%) pneumonitis events were reported. 範醖繭構壓繭鏇選積憲 (艱築顧蓋願醖窪窪淵鏇 )	积极	2024-09-07
				Carboplatin-etoposide
WCLC2024 人工标引	N/A	小细胞肺癌一线	135	Carboplatin plus Etoposide (EC) (extensive stage patients)	膚襯製遞壓夢窪遞遞築(積構鹽艱顧齋鏇製鏇憲) = 獵糧糧淵襯膚構鹽鹹遞網獵糧鏇窪壓顧餘顧觸 (顧鏇願夢獵築範繭繭選 ) 更多	积极	2024-09-07
				Cisplatin plus Etoposide (EP) (extensive stage patients)	膚襯製遞壓夢窪遞遞築(積構鹽艱顧齋鏇製鏇憲) = 糧糧壓築構鹹糧壓壓齋網獵糧鏇窪壓顧餘顧觸 (顧鏇願夢獵築範繭繭選 ) 更多